The effect of total anthocyanin-base standardized (Cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondialdehyde, and adiponectin in patients with non-alcoholic fatty liver: a study protocol for a double-blind randomized clinical trial

Zohreh Sadat Sangsefidi 1,2, Mahdieh Hosseinzadeh1,2, Ali Mohammad Ranjbar 3,4, Mohsen Akhondi-Meybodi 5, Hossein Fallahzadeh 6 and Hassan Mozaffari-Khosravi 1,2*

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Evidence showed that anthocyanins might have effects on NAFLD. Protective effects of Cornelian cherry (Cornus mas L.) extract, as an anthocyanins-rich source, on liver were reported in animal studies. However, very few clinical trials were conducted in this regard. Thus, the aim of this research will be to evaluate the effect of supplementation with total anthocyanin-base standardized cornelian cherry fruit extract on liver function (Serum levels of Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), cyto keratin-18 fragment M30 (CK-18 M30), as well as steatosis and fibrosis of liver), tumor necrosis factor α (TNF-α), malondialdehyde (MDA), and adiponectin in patients with NAFLD.

Methods: In a double-blind randomized clinical trial, 80 NAFLD patients will be studied. The patients will be randomly assigned into two groups. The intervention group will receive the cornelian cherry extract, containing 320 mg.d⁻¹ anthocyanins, per day for 12 weeks. The control group will also take the placebo daily for 12 weeks. Liver function (Serum levels of AST, ALT and CK-18 M30; steatosis and fibrosis of liver), serum levels of TNF-α, MDA, and adiponectin will be measured at the baseline and the end of trial for both groups and their results will be compared.

Discussion: Considering evidences about the useful impacts of anthocyanins on NAFLD, the effects of supplementation with cornelian cherry extract will be investigated on the important variables related to NAFLD.

Trial registration: Iranian Registry of Clinical Trials (IRCT2018041903935N1).

Keywords: Nonalcoholic fatty liver disease, Anthocyanins, Cornelian cherry, Cornus mas L

* Correspondence: mozaffari.kh@gmail.com
1Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases [1–4]. The overall prevalence of NAFLD was from 5 to 20% among the healthy populations and more than 40% in the diabetic patients [5, 6]. However, a recent systematic review showed that its total prevalence was 33.9% among Iranian people [7]. The detailed pathogenesis and etiology of the disease are still unknown [8–10]. Nevertheless, NAFLD may be associated with factors such as insulin resistance [10, 11], oxidative stress, and adipokines such as adiponectin, cytokines, and other inflammatory mediators [10, 12]. Insulin resistance increases lipolysis in adipose tissue, releases free fatty acids to liver, and causes inflammation in liver [10, 11]. Moreover, mitochondrial dysfunction, oxidative stress, and increased inflammatory responses are related to damaged liver [10, 12]. The low level of serum adiponectin was also observed in NAFLD patients, which was related to the rate of steatosis, fibrosis, and severity of NAFLD [13]. Since no definite treatment has been found for this disease, identification of new therapeutic approaches is one of the current challenges [10, 14, 15]. A study suggested that flavonoids such as anthocyanins, found in plant sources with red, purple, and blue colors [16] were effective in treating NAFLD [17]. According to the literature, the effects of anthocyanins on NAFLD include decrease of lipid accumulation in the liver [18–23], improvement of insulin resistance [24–27], decrease of lipid profile [23–26], inflammation [19, 26], and oxidative stress [28–32]. Moreover, some human studies reported useful effects of anthocyanins on the levels of liver enzymes such as ALT and AST [33, 34], oxidative stress markers such as MDA [35], inflammatory markers such as TNF-α [36, 37], lipid profile [35, 36, 38–40], glycemic control [38, 39], insulin resistance [40, 41] and adiponectin [41]. However, very few clinical trials evaluated the effect of anthocyanins [37, 42, 43] on NAFLD. For example, supplementation with purified anthocyanins for 12 weeks was associated with a significant decrease in the level of Alanine Aminotransferase (ALT) and cytokeratin-18 fragment M30 (CK-18 M30). However, it improved the fibrosis scores of NAFLD patients [42]. In addition, another research reported that intake of Hibiscus sabdariffa extract, rich in anthocyanins, for 12 weeks improved liver steatosis in patients with fatty liver [43]. A study found that consumption of bayberry juice, as a source of anthocyanins, for 4 weeks decreased the levels of TNF-α and CK-18 M30 among NAFLD patients [37]. Nevertheless, the earlier studies had various limitations: lack of precise examination of steatosis and fibrosis of liver by an accurate non-invasive method such as transient elastography (Fibroscan) [37, 42, 43], low study power [42], lack of assessing other important factors such as adipokines, adiponectin, as well as inflammatory and oxidative stress markers [37, 42, 43]. Recent evidences demonstrated that results of transient elastography, as a non-invasive method, had appropriate consistency with results of biopsy, as an invasive but gold standard method for assessing NAFLD. Therefore, transient elastography can replace biopsy as a more accurate and non-invasive method in evaluating NAFLD [44–46]. Cornus mas L. (cornelian cherry) is a fruit rich in anthocyanins [47]. Although its protective effects on liver was reported in several animal studies [48–51], no clinical trial has ever investigated the effect of cornelian cherry fruit extract on NAFLD. Considering the high prevalence of NAFLD as well as the limited number and limitations of clinical trials over the effect of anthocyanins on NAFLD, further clinical trials are required in this area. The future trials should conduct comprehensive investigations on important NAFLD variables and examine the impacts of anthocyanins on NAFLD. Therefore, the present double-blind randomized clinical trial will be conducted to investigate the effect of supplementation with total anthocyanin-base standardized cornelian cherry fruit extract on the liver function (Serum levels of AST, ALT and CK-18 M30; steatosis and fibrosis of liver), TNF-α, MDA, and adiponectin in patients with NAFLD. Furthermore, serum concentrations of glucose, total cholesterol (TC), High density lipoprotein (HDL-C), low density lipoprotein (LDL-C), triglyceride (TG), insulin, and insulin resistance will be evaluated as the secondary outcomes.

Methods
Design and aim study
This double-blind randomized parallel clinical trial will be carried out at the Department of nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. The main aim of this research is to investigate the effect of a 12-week supplementation with total anthocyanin-base standardized cornelian cherry fruit extract on liver function (Serum levels of AST, ALT and CK-18 M30; steatosis and fibrosis of liver), TNF-α, MDA, and adiponectin in patients with NAFLD. Furthermore, serum concentrations of glucose, total TC, HDL-C, LDL-C, TG, insulin, and insulin resistance will be assessed as the secondary outcomes.

Preparation of total anthocyanin-base standardized cornelian cherry fruit extract
Materials and extraction
Fresh ripe berries of cornelian cherry were prepared from the forests of Ghazvin, Iran, in October 2018 and frozen at –18°C. Later, the fruits’ authenticity will be determined by specifying their voucher number (SSU0029) in the Department of Pharmacognosy, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd. In the next stage, the fruits will be cleaned and their cores will be
removed. Then, the fruit samples will be grinded and mixed with the solvents including ethanol 80% and HCL 0.1%. Extraction will be performed by percolation for one week. Then, it will be followed by Ultrasound-Assisted Extraction (UAE) for 20 min using an ultrasonic device (Elmasonic Easy 60 H, German; frequency 50/60 Hz). After filtration of the obtained extract, it will be concentrated by evaporation.

**Total anthocyanin content determination**

The total anthocyanin content of the achieved extract will be determined using the pH differential method [52, 53]. Since the prepared extract does not have purified anthocyanins, the extract's total flavonoid/phenolic content should be measured. Furthermore, the necessary microbiology measurements will be performed for the prepared extract.

**Table 1** Study timeline; we predicted 20 months to carry out the present study

| Description of research activity                                    | Duration (month) |
|---------------------------------------------------------------------|------------------|
| Reviewing the literature and writing the proposal                   | *                |
| Preparing the total anthocyanin-base standardized (Cornus mas L.) fruit extract and the placebo | * * *             |
| Standardizing the extract based on the total anthocyanin            | *                |
| Selecting the participants                                          | * * *            |
| Collecting data, conducting the intervention and assessments        | * * *            |
| Entering the data into SPSS and conducting the statistical analysis| * * *            |
| Providing the final reports                                         | * * *            |

The symbol * represents the start and end time of each research activity in study timeline.
Preparation of placebo
The placebo will be prepared using diluted water, caramel color, allura red color, and natural flavorings with a color, appearance, taste, and texture similar to the cornelian cherry extract, but without any anthocyanins.

Study population
Patients with NAFLD will be selected based on the inclusion and exclusion criteria from gastroenterology clinics affiliated to Diabetes Research Center and Shahid Sadoughi University of Medical Sciences, Yazd, Iran. The inclusion criteria will be having 25–65 years of age; ALT levels of higher than 30 U/L in men and higher than 19 U/L in women; diagnosis of the disease by a gastroenterologist; and grade 1, 2, and 3 fatty liver. Furthermore, patients should be residents of Yazd city and will be required to sign the informed consent forms to participate in the research. In the current research, nonalcoholic steatohepatitis (NASH) will be defined based on the guidelines of American Gastroenterological Association and American Association for the Study of Liver Diseases [54]. According to this guideline, NASH is defined as the presence of hepatic steatosis proved by ultrasonography or inflammation with hepatocyte injury (ballooning) with or without fibrosis [54]. Moreover, NAFLD will be diagnosed by ultrasonography based on the following criteria: an increase in hepatic echogenicity via renal echogenicity as a reference, presence of enhancement and lack of differentiation of periportal, and bile duct walls reinforcement due to great hyperechogenicity of the parenchyma [55]. Exclusion criteria will include: having any history of diseases such as cirrhosis, viral hepatitis, cardiovascular disease, diabetes, Wilson, and cancer; taking medications including corticosteroids, non-steroidal anti-inflammatory drugs, hypoglycemic agents, or any medicines that affect the blood glucose, tamoxifen, sodium valproate, methotrexate, amiodarone, anti-retroviral agents for HIV, probiotics; consuming any medicine or supplement that affect liver function as well as supplements with antioxidant and anti-inflammatory properties such as vitamin D, vitamin E, omega-3, resveratrol) one month before the study; following a special diet one month before the study; being pregnant and breastfeeding; and consuming alcohol. We will also ask the patients to not consume the medicines in exclusion criteria list during the study. Moreover, data of the patients with any of the following conditions will not be analyzed at the end of study: patients who take less than 80% of the administered extract or placebo as well as participants who are under a special treatment due to a specific medical reason during the study.

Ethical considerations and trial registration
This survey was approved by Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran (approval number: IR.SSU.SPH.REC.1396.171). The research was also registered on Iranian Registry of Clinical Trials (IRCT registration code: IRCT2018041903935N1). After informing the participants about the study protocol, they will be asked to sign the informed consent forms.

Sample size
To estimate the sample size, we considered 95% confidence interval; 80% power ($\alpha = 0.05$ and $\beta = 0.2$); the changes of ALT levels in intervention group compared with the control group, and $S = 24\%$ to achieved the significance level of 16% in both study groups according to the study by Zhang et al. [42]. Therefore, the sample size was calculated as $n = 36$ for each group. Eventually, 40 patients will be recruited for each group considering the possible 10% loss.

Randomization
Eligible patients will be assigned into two groups ($n = 40$ in each group) of the cornelian cherry fruit extract and the placebo group using the randomization method, which will be performed using the Random Allocation Software [56]. The participants will be also stratified based on age, gender, BMI, and severity of fatty liver (fatty liver grade 1, 2, 3).

Intervention
The target daily dose of 320 mg.d$^{-1}$ of total anthocyanin will be administered for 12 weeks [42]; with the required daily intake of extract adjusted in accordance with the total anthocyanin content measured in the extract. Moreover, the total anthocyanin content in the extract will be measured in distinct intervals during the trial (on days 1, 6, 12, 20, and after 6 months). If it is required, we will adjust the amount of consumed extract based on its total anthocyanin content.

The control group will also receive the placebo, matched with the extract in terms of appearance, taste, color, and texture (but without any anthocyanins) for 12 weeks. The participants will be asked to keep the intervention and placebo, which are presented as liquid in the refrigerator to ensure food safety.

In the current double-blind randomized clinical trial, the cornelian cherry extract and the placebo will be packed in containers with the same color, shape, and size, so that they cannot be identifiable by the patients or administrators. A person out of research, who does not know about the details of study, will be asked to label the bottles containing the extract or placebo as A or B, the contents of these bottles should be consumed in one month by participants. This person will be asked to inform the researchers about his/her labeling selection at the end of study. We will also ask the participants to give back their bottles (empty or not) at the end of each month and receive the next bottles until the end of
study. At the end of intervention, the remaining contents of bottles will be recorded for each participant. Moreover, regular consumption of the extract or placebo will be checked by contacting the patients during the survey. At the end of the trial, the consumed amounts of extract or placebo will be estimated considering the remaining contents of the bottles for each participant. In the case that a patient in each group consumed less than 80% of the administered extract or placebo, his/her data will not be analyzed at the end of the study.

Data collection
Data on patients’ demographic information, history of diseases, and consumption of medications or supplementations will be collected using a general questionnaire at the beginning of the research.

Participants’ dietary intakes will be evaluated using a three-day food record (2 week days and 1 weekend day) at the baseline and at the end of trial. Then, to estimate the total energy and macronutrients’ intakes, Nut IV (the Hearst Corporation, San Bruno, CA) will be used. Moreover, in order to evaluate the patients’ physical activity levels, the short form of International Physical Activity Questionnaire (IPAQ) will be administered at the beginning and the end of survey. Meanwhile, anthropometric parameters (e.g., weight, height, Body Mass Index (BMI), and waist and hip circumference) will be measured with minimal clothing and without shoes at the baseline and at the end of study. Body weight will be assessed by a seca scale with an accuracy of 100 g. Height will be measured in a relaxed position with the accuracy of 0.5 cm by a seca stadiometer. Then, BMI will be calculated after dividing the body weight (kg) by the square of height (m). Waist circumference will be also measured at the midway between the lowest ribs and the iliac crest. Moreover, hip circumference will be measured over the largest part of the buttocks.

Outcomes measurements
At the baseline and at the end of the research, 10 ml of blood sample will be taken from each participant after 10–12 h of overnight fasting for biochemical analyses.

Primary outcomes
At the baseline and at the end of trial, serum concentrations of Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) will be measured with an autoanalyzer. Serum levels of TNF-α, MDA, adiponectin, and CK-18 M30 will be also determined by Enzyme-linked immunosorbent assay (ELISA).

Furthermore, hepatic steatosis and liver fibrosis will be examined using transient elastography by a gastroenterologist at the baseline and at the end of the survey. Evaluation will be conducted while patients are lying in a dorsal decubitus position with their right arm in maximum abduction [57].

Secondary outcomes
At the baseline and at the end of the study, serum concentrations of glucose, total cholesterol (TC), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), and triglyceride (TG) will be determined by an autoanalyzer. Serum levels of insulin will be also measured by ELISA.

Moreover, insulin resistance will be evaluated at the baseline and at the end of trial by the following two methods:

- Homeostasis model assessment – insulin resistance (HOMA-IR) = fasting insulin (μU/ml) × fasting glucose (mg/dl)/405.
- Quantitative insulin sensitivity check index (QUICKI) = 1/log fasting insulin (μU/ml) + log fasting glucose (mg/dl).

Statistical analysis
Data analysis will be conducted using SPSS version 24 (SPSS Inc., Chicago, IL, USA). The normality of variables will be evaluated using Kolmogorov-Smirnov test. Qualitative and quantitative variables will be presented as numbers (percentages) and mean ± Standard Deviation (SD) or medians with interquartile ranges, respectively. Then, the Chi-Squared test will be used to compare the qualitative variables between two groups. In addition, the variables with normal distribution will be compared between and within the groups using the independent sample t-test and the paired sample t-test, respectively. However, in order to compare the variables with non-normal distribution between and within the groups, Mann-Whitney test and Wilcoxon test will be applied, respectively. To control the confounding variables, analysis of covariance (ANCOVA) will be used to examine the differences in post-intervention values between the two groups while adjusting for the baseline values and covariates. A p-value of < 0.05 will be considered as the statistically significant level.

Discussion
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases with an increasing prevalence throughout the world. Since no certain therapy has been found for NAFLD yet, determination of new and effective treatments is one of the substantial challenges of the current researchers. Recently, studies indicated that anthocyanins had some impacts on NAFLD. In addition, the protective effects of cornelian cherry fruit extract, as an anthocyanins-rich source, on liver were reported in animal studies. However, very few clinical trials investigated the
impact of anthocyanins on NAFLD and we are faced with paucity of information on the disease and its main limitations. Therefore, further clinical trials with a more comprehensive assessment of important variables related to NAFLD are needed to evaluate the impact of anthocyanins on patients with NAFLD. Therefore, we will examine the effect of supplementation with total anthocyanin-base standardized cornelian cherry fruit extract on liver function, TNF-α, MDA, and adiponectin in NAFLD patients. The findings of this study can provide new information over the impact of total anthocyanin-base standardized cornelian cherry fruit extract, as an anthocyanins-rich source, on NAFLD. It also paves the way to discover new approaches for treatment of the disease.

**Abbreviations**

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body Mass Index; CK: 18 M30: Cytokeratin-18 fragment M30; ELISA: Enzyme-linked immunosorbent assay; HDL-C: High density lipoprotein; HOMA-IR: Homeostasis model assessment – insulin resistance; IPAQ: International Physical Activity Questionnaire; LDL-C: Low density lipoprotein; MDA: Malondialdehyde; NAFLD: Nonalcoholic fatty liver disease; QUICKI: Quantitative insulin sensitivity check index; SD: Standard Deviation; TC: Total cholesterol; TG: Triglyceride; TNF-α: Tumor necrosis factor α

**Acknowledgements**

The authors appreciate Shahid Sadoughi University of Medical Sciences, Yazd, Iran for supporting this research.

**Trial status**

The present research is at the stage of preparing the total anthocyanin-base standardized cornelian cherry fruit extract and the placebo.

**Authors’ contributions**

All authors were involved in designing the study and drafting the protocol. All authors read and approved the final version of the protocol.

**Funding**

No funding was received regarding to this survey.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

The present study was approved by the Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran (approval number: IR.SSU.SPH.REC.1396.171). Moreover, this research was registered on Iranian Registry of Clinical Trials (IRCT registration code: IRCT201801419039359N1). The informed consent forms will also be collected from all participants.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3Department of Pharmacognosy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 4Herbal Medicine Center, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 5Gastroenterology Department, Shahid Sadoughi Hospital, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 6Research Center of Prevention and Epidemiology of Non-Communicable Disease, Departments of biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Received: 8 January 2019 Accepted: 8 July 2019
Published online: 19 July 2019

**References**

1. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clinics in liver disease. 2007;11(1):1–16.
2. Feldstein AE, editor Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Seminars in liver disease; 2010: © Thieme Medical Publishers.
3. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861.
4. Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009;41(9):615–25.
5. Lazo M, Clark JM, editors. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in liver disease; 2008: © Theme Medical Publishers.
6. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(S5-S10).
7. Moghadassifar I, Lankarani K, Moosazadeh M, Afshari M, Ghaemi A, Aliarizemany M, et al. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Int J Organ Transplant Med. 2016;7(3):149.
8. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46(4):272–84.
9. Tlg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(3):1836–46.
10. Van De Weer B, Koek GH, Bast A, Haenen GR. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr. 2017;57(4):834–55.
11. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753–61.
12. Wei Y, Rector RS, Thfyault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol: WJG. 2008;14(2):193.
13. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12(5):635–83.
14. Chaisani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.
15. Nascimbenti F, Pais R, Bellentani S, Day CP, Ratsuiv V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):785–791.
16. Bueno JM, Sáez-Plaza P, Ramos-Escudero F, Jiménez AM, Fett R, Asuero AG. Analysis and antioxidant capacity of anthocyanin pigments. Part II: chemical structure, color, and intake of anthocyanins. Crit Rev Anal Chem. 2012;42(2):126–51.
17. Valenti L, Riso P, Mazzocchi A, Pennini M, Fangion S, Agostoni C. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. OXidative Med Cell Longev 2013;2013.
18. Guo H, Li D, Ling W, Feng X, Xia M. Anthocyanin inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKCζ, J Lipid Res. 2011;52(5):908–22.
19. Guo H, Liu G, Zhong R, Wang Y, Wang D, Xia M. Cyanidin-3-O-b-glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. Lipids Health Dis. 2012;11(1):10.
20. Ja Y, Kim J-Y, Jun H-J, Kim S-J, Lee J-H, Hoang MH, et al. Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2013;1831(4):698–708.
21. Chang J, Hsu M-J, Huang H-P, Chung D-J, Chang Y-C, Wang C-J. Mulberry anthocyanins inhibit oleic acid induced lipid accumulation by reduction of lipogenesis and promotion of hepatic lipid clearance. J Agric Food Chem. 2013;61(25):6069–76.
22. Hwang YP, Choi JH, Han EH, Kim HG, Wee J-H, Jung KO, et al. Purple sweet potato anthocyanins attenuate hepatic lipid accumulation through
activating adenosine monophosphate–activated protein kinase in human HepG2 cells and obese mice. Nutr. Res. 2011;31(12):896–906.

23. Peng C-H, Liu L-K, Chuang C-M, Chuy C-C, Huang C-N, Wang C-J. Mulberry water extracts possess an anti-obesity effect and ability to inhibit hepatic lipogenesis and promote lipolysis. J Agric Food Chem. 2011;59(9):2663–71.

24. Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr Biochem. 2012;23(4):349–60.

25. Seymour EM, Tanone II, Urcuyo-Llanes DE, Lewis SK, Kirakosyan A, Kondoleon MG, et al. Blueberry intake alters skeletal muscle and adipose tissue peroxisome proliferator-activated receptor activity and reduces insulin resistance in obese rats. J Med Food. 2011;14(12):1511–8.

26. Seymour EM, Singer AG, Krakoysan A, Urcuyo-Llanes DE, Kaufman PB, Bolling SF. Altered hyperlipidemia, hepatic steatosis, and hepatic peroxisome proliferator-activated receptors in rats with intake of tart cherry. J Med Food. 2008;11(2):252–9.

27. Salamone F, Volti GL, Titta L, Puzzo L, Barbagallo L, La Dela F, et al. Moro orange juice prevents fatty liver in mice. World J Gastroenterol: WJG. 2012; 18(29):3862.

28. Liu Y, Wang D, Zhang D, Ly Y, Wei Y, Wu W, et al. Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro. J Agric Food Chem. 2011;59(22):12546–53.

29. Dubey P, Jayasooriya AP, Cheema SK. Fish oil induced hyperlipidemia and oxidative stress in BioF1B hamsters is attenuated by elderberry extract. Appl Physiol Nutr Metab. 2012;37(3):472–9.

30. Cho BO, Ryu HW, Jin CH, Choi DS, Kang SY, Kim DS, et al. Blackberry extract attenuates oxidative stress through up-regulation of Nrf2-dependent antioxidant enzymes in carbon tetrachloride-treated rats. J Agric Food Chem. 2011;59(21):11442–8.

31. Zhu W, Jia Q, Wang Y, Zhang Y, Xia M. The anthocyanin cyanidin-3-O-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: involvement of a cAMP–PKA-dependent signaling pathway. Free Radic Biol Med. 2011;52(2):314–27.

32. Takayama F, Nakamoto K, Kasawaki H, Mankura M, Egashira T, Ueki K, et al. Beneficial effects of Vitis coignetiae Pullat leaves on nonalcoholic steatohepatitis in a rat model. Acta Med Okayama. 2009;63(2):105–11.

33. Oki T, Kano M, Ishikawa F, Goto K, Watanabe O, Suda I. Double-blind, placebo-controlled pilot trial of anthocyanin-rich purple sweet potato beverage on serum hepatic biomarker levels in healthy Caucasians with borderline hepatitis. Eur J Clin Nutr. 2017;71(2):290.

34. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705–13.

35. Di Giacomo A, Calvarano M, Calvarano I, Di Giacomo G, Belmusto G. Il succo delle arance pigmentate italiane. Essenze Deriv Agrum. 1989;59:273–8.

36. Massouh MM, Badea R, Stefnescu H, Grigorescu M, Serban A, Radu C, et al. Hepatoprotective effect of Cornus mas L. (cornelian cherry), an important European and Asian traditional food and medicine: Ethnomedicine, phytochemistry and pharmacology for its commercial utilization in drug industry. J Ethnopharmacol. 2016;193:670–90.

37. Abbasi MM, Abololabi B, Milani PZ, Mohajeri D, Nourdadgar AS. Effects of hydro-methanolic extract of cornus mas on histopathological and biochemical parameters of rats’ liver and kidney. Bothalia J. 2014;44(4):290–59.

38. Rapidasaru P, Fanea F, Maccarone E. Reliability of analytical methods for determining anthocyanins in blood orange juices. J Agric Food Chem. 2000;48(6):2349–52.

39. Di Giacomo A, Calvarano M, Calvarano I. Di Giacomo G, Belmonto G. Il succo delle arance pigmentate italiane. Essenze Deriv Agrum. 1989;59:273–8.

40. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.

41. Somi MH, Banhabib N, Dehghani K, Panahi F. Hepatoprotective effect of Cornus mas fruits extract against carbon tetrachloride-induced hepatic damage in male albino rats. Thrita. 2014;3(2).

42. Zhang P-W, Chen F-X, Li D, Ling W-H, Guo H-H. A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. Medicine. 2015;94(20):e758.

43. Chang H-C, Peng C-H, Yeh D-M, Kao E-S, Wang C-J. Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans. Funct. Foods. 2014;5(4):734–9.

44. Kwok R, Tse YK, Wong GH, Ha Y, Lee A, Ngu M, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease: the role of transient elastography and plasma cytokerin-18 fragments. Aliment Pharmacol Ther. 2014;39(3):254–69.

45. Hu K-C, Wang H-Y, Liu S-C, Liu C-C, Hung C-L, Bair M-J, et al. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol: WJG. 2014;20(24):7718.

46. Haschemi S-A, Alavian S-M, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Caspian J Inter Med. 2016;7(4):242.

47. Daneshzad E, Shab-Bidar S, Mohammadpour Z, Djafarian K. Effect of blueberry intake alters skeletal muscle and adipose tissue peroxisome proliferator-activated receptor activity and reduces insulin resistance in obese rats. J Med Food. 2011;14(12):1511–8.